Gene ID number

7048

Modification site(s)

Tyr259

Swiss Prot

P37173

French translation

anticorps

Subcellular location

Cytoplasm

Immunogen range

250-270/567

Concentration

1ug per 1ul

Conjugation

Unconjugated

Target Antigen

TGFBR2 Tyr259

Modification(s)

Phosphorylation

Cross reactivity

Human, Mouse, Rat

Also known as

TGFBR2 Tyr259 PAb

Category

Primary Antibodies

Clonality

Polyclonal antibody

Clone number

Polyclonal antibody

Tested Applications

WB, IHC-P, IF(IHC-P)

Long name

TGFBR2 Tyr259 Primary Polyclonal Antibody

Purification method

This antibody was purified via Protein A.

Recommended dilutions

WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)

Specificity

This is a highly specific antibody against TGFBR2 Tyr259.

Cross reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

KLH conjugated synthesised phosphopeptide derived from human TGF beta Receptor II around the phosphorylation site of Tyr259

Storage conditions

Keep the antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for up to 1 year.

Properties

If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Synonym names

AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFbeta-RII; TGF-beta receptor type-2; TGF-beta type II receptor; Transforming growth factor-beta receptor type II; TGF-beta receptor type II; TbetaR-II; TGFBR2

Background of the target antigen

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.